Matiukhova Margarita, Ryapolova Anastasia, Andriianov Vladimir, Reshetnikov Vasiliy, Zhuravleva Sophia, Ivanov Roman, Karabelsky Alexander, Minskaia Ekaterina
Translational Medicine Research Center, Sirius University of Science and Technology, Sochi, Russia.
Front Cell Dev Biol. 2025 May 8;13:1593207. doi: 10.3389/fcell.2025.1593207. eCollection 2025.
The ability to reprogram mature, differentiated cells into induced pluripotent stem cells (iPSCs) using exogenous pluripotency factors opened up unprecedented opportunities for their application in biomedicine. iPSCs are already successfully used in cell and regenerative therapy, as various drug discovery platforms and for disease modeling. However, even though already 20 years have passed since their discovery, the production of iPSC-based therapies is still associated with a number of hurdles due to low reprogramming efficiency, the complexity of accurate characterization of the resulting colonies, and the concerns associated with the safety of this approach. However, significant progress in many areas of molecular biology facilitated the production, characterization, and thorough assessment of the safety profile of iPSCs. The number of iPSC-based studies has been steadily increasing in recent years, leading to the accumulation of significant knowledge in this area. In this review, we aimed to provide a comprehensive analysis of methods used for reprogramming and subsequent characterization of iPSCs, discussed barriers towards achieving these goals, and various approaches to improve the efficiency of reprogramming of different cell populations. In addition, we focused on the analysis of iPSC application in preclinical and clinical studies. The accumulated breadth of data helps to draw conclusions about the future of this technology in biomedicine.
利用外源性多能性因子将成熟的分化细胞重编程为诱导多能干细胞(iPSC)的能力,为其在生物医学中的应用带来了前所未有的机遇。iPSC已成功应用于细胞和再生治疗、各种药物发现平台以及疾病建模。然而,尽管自iPSC发现以来已经过去了20年,但由于重编程效率低、对所得克隆进行准确表征的复杂性以及与该方法安全性相关的担忧,基于iPSC的疗法的生产仍然面临许多障碍。然而,分子生物学许多领域的重大进展促进了iPSC的生产、表征以及对其安全性概况的全面评估。近年来,基于iPSC的研究数量一直在稳步增加,导致该领域积累了大量知识。在这篇综述中,我们旨在对用于iPSC重编程及后续表征的方法进行全面分析,讨论实现这些目标的障碍以及提高不同细胞群体重编程效率的各种方法。此外,我们重点分析了iPSC在临床前和临床研究中的应用。积累的数据广度有助于得出关于该技术在生物医学中未来发展的结论。